Safest DOAC in Chronic Kidney Disease

DOAC Characteristics in CKD

Apixaban has the lowest renal clearance at 27%, making it the least dependent on kidney function for elimination 1, 2
Edoxaban has 50% renal clearance and requires dose reduction more rapidly in declining renal function 1
Rivaroxaban has intermediate renal clearance (35%) and requires less dose reduction (by 25%) compared to edoxaban 1
Dabigatran has the highest renal clearance (80%) and is contraindicated in Europe for severe CKD (CrCl <30 mL/min) 1, 2

The American College of Cardiology recommends that all DOACs are approved and can be used with appropriate dose adjustments for mild to moderate CKD (CKD Stage 1-3, CrCl ≥30 mL/min) 3, 4
The American College of Cardiology suggests that DOACs are preferred over vitamin K antagonists (VKAs) due to superior safety and efficacy for mild to moderate CKD (CKD Stage 1-3, CrCl ≥30 mL/min) 4
Systematic reviews show DOACs reduce stroke/systemic embolism (OR: 0.79) and major bleeding (OR: 0.74) compared to warfarin in moderate CKD 4
Apixaban is preferred for severe CKD (CKD Stage 4, CrCl 15-29 mL/min) due to its lowest renal clearance (27%) and demonstrated increasing relative safety vs. warfarin as renal function declines 1, 2
Edoxaban (50% renal clearance) may be considered as an alternative for severe CKD (CKD Stage 4, CrCl 15-29 mL/min) 1
Rivaroxaban (35% renal clearance) is approved but with less favorable bleeding profile than apixaban for severe CKD (CKD Stage 4, CrCl 15-29 mL/min) 1, 2
Dabigatran is contraindicated in Europe for severe CKD; in the US, a reduced dose (75mg BID) is approved based only on pharmacokinetic simulations 1, 5

Limited high-quality evidence exists for any oral anticoagulant in this population 6, 3
Apixaban 5mg BID is approved for chronic, stable dialysis patients in the US, though plasma levels may be supra-therapeutic 6
Apixaban 2.5mg BID may provide more appropriate drug levels in dialysis patients 6

Renal function should be monitored at least yearly in all patients on DOACs 1, 2
For patients with CrCl <60 mL/min, more frequent monitoring is recommended (minimum frequency in months = CrCl/10) 1, 2
Additional monitoring is needed during acute illness (infections, heart failure) that may transiently affect renal function 2
Patients should be educated to contact healthcare providers during acute illnesses 2

Dabigatran should be avoided in severe CKD due to high renal clearance (80%) and increased bleeding risk 1, 2
Warfarin use in advanced CKD may increase risk of vascular calcification, calciphylaxis, and anticoagulant-related nephropathy 3, 7
Plasma levels of DOACs may accumulate in severe CKD despite dose adjustments, increasing bleeding risk 8
Inconsistencies exist between FDA and EMA approvals for DOACs in severe CKD and dialysis 5, 7
Regulatory authorities use creatinine clearance (CrCl) while many clinical guidelines use eGFR, creating potential confusion in dosing recommendations 5